Compound suitable for the treatment of synucleopathies

Abstract

The present invention relates to certain heteroaromatic compounds of Formula (Ia), or pharmaceutically acceptable salts thereof, and uses of such compounds in the treatment of synucleopathies.

1 - 16 . (canceled) 
     
     
         17 . A compound of Formula (Ia): 
       
         
           
           
               
               
           
         
         wherein 
         R 1  is a hydrophilic aromatic or heterocyclic group; 
         R 2  is an aliphatic hydrocarbon or alicyclic hydrophobic group or nil; 
         R 3  is an aliphatic or alicyclic group with basic character; 
         X is NH, O, S, or CH 2 ; 
         Y is C═O, C═S, or C═NH; 
         each Z is independently C, CH, C═O, O, S, —N—, or NH; and 
         L is CH 2 , CO 2 , CH 2 —S, CH 2 —SO, CH 2 —SO 2 , O, S, or C═O, or nil; 
         or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate of said compound or salt. 
       
     
     
         18 . The compound of  claim 17 , wherein
 Z 1  is C or N;   Z 2  is C, N, C═O, or NH;   Z 3  is C═O, N, or C;   Z 4  is C; and   Z 5  is N, S, NH, O, C═O, or S.   
     
     
         19 . The compound of  claim 17 , wherein R 1  is a bicyclic heteroaromatic group. 
     
     
         20 . The compound of  claim 19 , wherein R 1  is selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
     
     
         21 . The compound of  claim 17 , wherein R 2  is an aliphatic hydrocarbon or alicyclic hydrophic group. 
     
     
         22 . The compound of  claim 17 , wherein R 2  is an alkyl group with 1 to 8 carbon atoms. 
     
     
         23 . The compound of  claim 17 , wherein R 2  is an alkyl group with 1 to 5 carbon atoms. 
     
     
         24 . The compound of  claim 17 , wherein R 2  is selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
     
     
         25 . The compound of  claim 17 , wherein R 3  is: 
       
         
           
           
               
               
           
         
       
     
     
         26 . The compound of  claim 17 , wherein 
       
         
           
           
               
               
           
         
       
       is selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
     
     
         27 . The compound according to  claim 17 , selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         and pharmaceutically acceptable salts thereof. 
       
     
     
         28 . A pharmaceutical composition comprising a compound of  claim 17  or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients. 
     
     
         29 . A method of treating a synucleopathy comprising administering to a patient in need of such treatment an effective amount of a compound of  claim 17  or a pharmaceutically acceptable salt thereof. 
     
     
         30 . The method of  claim 29 , wherein the synucleopathy is Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, Pick's disease, Down syndrome, multiple system atrophy, amyotrophic lateral sclerosis (ALS), or Hallervorden-Spatz syndrome.